Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the PK Similarity of AK104 (Anti-PD-1/CTLA-4 Bispecific Antibody) From the Proposed New Manufacturing Site and the Approved Original Site in Chinese Healthy Male Participants.

NCT07619001 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT07619001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the PK Similarity of AK104 (Anti-PD-1/CTLA-4 Bispecific Antibody) From the Proposed New Manufacturing Site and the Approved Original Site in Chinese Healthy Male Participants.
Lead sponsor
Akeso
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
December 30, 2026
Enrollment
158 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy male adults participants